Method and apparatus for separating a material

Information

  • Patent Grant
  • 9533090
  • Patent Number
    9,533,090
  • Date Filed
    Thursday, November 21, 2013
    11 years ago
  • Date Issued
    Tuesday, January 3, 2017
    7 years ago
Abstract
A separation system for separating a multiple component material into at least two fractions. The separation system includes a separation device having a first end, a second end opposite to the first end, and a sidewall that extends between the first end and the second end to define a separation chamber having an interior volume. The system also includes a valve moveable between an open position and a closed position, the valve is mounted at a fixed location within the separation chamber at a position that is closer to the second end than to the first end and is spaced apart from the second end, the valve is operable to isolate a first fraction of the multiple component material having a first density on a first side of the valve from a second fraction having a second density on a second side of the valve that is opposite to the first side.
Description
FIELD

The present disclosure relates to methods and apparatuses for separating biological materials, such as a selected fraction from a multiple component biological material.


BACKGROUND

This section provides background information related to the present disclosure, which is not necessarily prior art.


Various cellular or biological materials can be used to facilitate the healing or recovery process in a human patient. Selected cell types, such as stromal cells, pluripotent or multipotent stem cells, or fully differentiated cells can be applied therapeutically to the patient. For example, stem cells can be applied to an affected area of the patient, such as an area that may be damaged due to injury, chemotherapy, or radiation therapy, to assist in healing the area through differentiation of the stem cells and regeneration of the affected cells.


In performing a therapeutic procedure on a human patient using undifferentiated cells, such as stem cells or stromal cells, the undifferentiated cells can be obtained from various sources, including the patient's own anatomy. Accordingly, certain autologous cells can be applied to or injected into various portions of the patient's anatomy. Generally, a whole tissue, such as adipose tissue, or whole blood sample, can be obtained from the patient during a first procedure, selected cells can be separated from the whole tissue or blood sample, and the selected, separated cells can be reapplied to or injected into the patient during a subsequent procedure.


SUMMARY

This section provides a general summary of the disclosure, and is not a comprehensive disclosure of its full scope or all of its features.


The present teachings provide for a separation system for separating a multiple component material into at least two fractions. The separation system includes a separation device having a first end, a second end opposite to the first end, and a sidewall that extends between the first end and the second end to define a separation chamber having an interior volume. The system also includes a valve moveable between an open position and a closed position, the valve is mounted at a fixed location within the separation chamber at a position that is closer to the second end than to the first end and is spaced apart from the second end, the valve is operable to isolate a first fraction of the multiple component material having a first density on a first side of the valve from a second fraction having a second density on a second side of the valve that is opposite to the first side.


The present teachings further provide for a separation system for separating a multiple component material into at least two fractions that includes a separation device and a valve. The separation device has a first end, a second end opposite to the first end, and a sidewall that extends between the first end and the second end to define a separation chamber having an interior volume. The valve is mounted at a fixed positioned within the separation chamber at a position that is closer to the second end than to the first end and is spaced apart form the second end. The valve includes a screen, a flexible valve actuation member, and a sealing member. The flexible valve actuation member is movable in response to gravitational forces applied to the separation device. The sealing member is supported by the flexible valve actuation member. The flexible valve actuation member and the sealing member extend in a plane perpendicular to a longitudinal axis of the separation chamber and the sealing member contacts the screen to prevent the passage of materials through the screen when the valve is in a closed position. The flexible valve actuation member and the sealing member bend toward the second end when the valve is in an open position in response to gravitational forces exerted upon the separation device such that the sealing member is spaced apart from the screen to permit the passage of material through the screen.


The present teachings also provide for a method for isolating at least two fractions of a multiple component material. The method includes the following: loading the multiple component material into a separation chamber of a separation device between a valve mounted at a fixed position in the separation chamber and a first end of the device, the first end is opposite to a second end and a sidewall extends between the first end and the second end to define the separation chamber having an interior volume; centrifuging the separation device such that the valve moves to an open position in response to gravitational forces exerted on the device to permit a first fraction of the multiple component material of a first density to pass through the valve toward the second end; ceasing centrifugation of the separation device to permit the valve to move to a closed position, thus isolating the first fraction of the first density between the valve and the second end and isolating a second fraction of a second density that is less dense than the first density between the valve and the first end; and withdrawing at least one of the first fraction and the second fraction from the separation chamber for use in a subsequent procedure.


Further areas of applicability will become apparent from the description provided herein. The description and specific examples in this summary are intended for purposes of illustration only and are not intended to limit the scope of the present disclosure.





DRAWINGS

The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.



FIG. 1 is a side view of a separation device according to the present teachings;



FIG. 2 is a side cross-sectional perspective view taken along line 2-2 of FIG. 1 illustrating a valve according to the present teachings in a closed position;



FIG. 3 is a side cross-sectional perspective view of the valve of FIG. 2 in an open position;



FIG. 4 is an exploded perspective view of the valve;



FIG. 5 is a side cross-sectional perspective view of another valve according to the present teachings;



FIG. 6 is a partially cut-away side view of the separation device being filled with a multiple component material, such as adipose tissue, for separation into at least two fractions;



FIG. 7 is a perspective view of a centrifuge for spinning the device in order to separate the multiple component material into at least two fractions, such as cellular material and purified fat when the multiple component material is adipose tissue;



FIG. 8 is a partially cut-away side view of the separation device with the valve open, thus permitting passage of at least one fraction of the multiple component material there through, such as cellular material where the multiple component material is adipose tissue;



FIG. 9 is a partially cut-away side view of the separation device showing separated fractions being extracted from the separation device;



FIG. 10 illustrates delivery of one or more of the separated fractions being delivered to a selected site in a patient;



FIG. 11 illustrates extraction of the multiple component material directly from a patient into the separation device using a vacuum pump;



FIG. 12 is similar to FIG. 11, but includes the use of a disruption chamber attached to the separation device; and



FIG. 13 is a cross-sectional view of FIG. 12 taken along line 13-13 of FIG. 12.





Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings.


DETAILED DESCRIPTION

Example embodiments will now be described more fully with reference to the accompanying drawings.


With initial reference to FIGS. 1-3, a separation device in accordance with the present teachings is illustrated at reference numeral 10. The separation device 10 generally includes a first end 12, a second end 14 that is opposite to the first end 12, and a sidewall 16 that extends between the first end 12 and the second end 14. The sidewall 16 defines a separation chamber 17 of the separation device 10 having an interior volume. The sidewall 16 can be cylindrical. As illustrated, the first end 12 and the second end 14 can be positioned in spaced apart, parallel planes that are perpendicular to a longitudinal axis A of the separation chamber 17. The separation chamber 17 can have an interior volume of any suitable size, such as 90 ml, with any suitable diameter, such as 1.35 inches.


With additional reference to FIG. 4, a valve 18 is mounted at a fixed position within the separation chamber 17. Thus, the valve 18 does not move along the longitudinal axis A of the chamber 17. The valve 18 includes a grate or screen 20. The grate 20 is generally cylindrical and includes a center opening 22 with a series of radially extending spokes 24 extending therefrom. Each of the spokes 24 define an opening or passageway 25 therebetween. The spokes 24 terminate at a cylindrical outer wall 26. As illustrated, the passageways 25 are pie-shaped. However, the openings can be of any suitable shape, such as square or circular, as described below.


The grate 20 is surrounded by an annular insert 28 having a conical surface 30 that is angled toward the grate 20 to direct materials on the conical surface 30 toward the grate 20. The insert 28 has an outer diameter 32 that approximates an inner diameter of the separation chamber 17, such that no material can pass around the insert 28. The grate 20 and the opening 22 defined by the grate 20 provide support and alignment for a second extraction tube 72, which is further described herein. In place of the grate 20, any suitable screen with or without an opening therein can be used. Further, the grate 20 may be optional and the device 10 can be provided with the grate 20 removed and an opening provided in its place.


The valve 18 further includes a sealing member 34 and a support or valve actuation member 36. As illustrated, the sealing member 34 and the valve actuation member 36 can be aligned along the longitudinal axis A of the separation chamber 17. The sealing member 34 is generally shaped as a cylindrical disk and includes an opening 38 at its axial center. The sealing member 34 can be made of any suitable material, including a flexible material, such as a silicone rubber material. The sealing member 34 is sized to seal the plurality of passageways 25.


The valve actuation member 36 can include a cylindrical disk 40 and a mounting tube 42 extending therefrom along a longitudinal axis of the valve actuation member 36. The cylindrical disk 40 has a circumference that is substantially similar to that of the sealing member 34. The cylindrical disk 40 includes an opening 44 at its axial center. As further described herein, the cylindrical disk 40 provides support for the sealing member 34 to position the sealing member 34 against the grate 20 and prevent the passage of materials through the passageways 25 when the valve 18 is in the closed position. Further, the cylindrical disk 40 is flexible in response to gravitational forces, such as those experienced during centrifugation, to move the sealing member 34 from contact with the grate 20 and permit the passage of materials through the passageways 25 when the valve 18 is in the open position.


The mounting tube 42 extends from the cylindrical disk 40 along the axial center of the cylindrical disk. The mounting tube 42 has a circumference that is generally smaller than the circumference of the cylindrical disk 40. Proximate to a distal end 46 of the mounting tube 42 is at least one aperture 48. As illustrated, the distal end 46 includes four of the apertures 48, which are spaced evenly about the mounting tube 42 at approximately 90° intervals. A through port 50 extends between the apertures 48 and the opening 44 to provide fluid communication through the valve actuation member 36.


The cylindrical disk 40 of the valve actuation member 36 can be formed of any suitable material that can flex when a force is applied to it, such as a centrifugal force or a pressure differential force. For example, the disk 40 can be any resilient member operable to bias the valve 18 in a closed position such that the sealing member 34 blocks the passage of materials through the passageways 25. Material selected for the cylindrical disk 40 can include acrylic, polycarbonate, and any other appropriate resilient, flexible, and substantially inert material. The sealing member 34 can be mounted to the cylindrical disk 40 in any suitable manner, such as by using a suitable adhesive. Alternatively, the sealing member 34 can be a coating on the disk 40 and/or integral with the disk 40. The sealing member 34 can also be a separate component that is not secured to the disk 40, but rather sits thereon and is supported by the disk 40.


The assembled valve 18 is positioned within the separation chamber 17 such that the distal end 46 of the mounting tube 42 abuts the second end 14 of the chamber 17, which may include a funnel 52 as further described herein. The grate 20, the sealing member 34, and the valve actuating member 36, are each positioned such that the center opening 22, the opening 38, and the opening 44 respectively are all aligned along the longitudinal axis A. When the valve is in the closed position as illustrated in FIG. 2, the cylindrical disk 40 supports the sealing member 34 against the grated portion 20 of the insert 28 to block and seal the passage of materials through the passageways 25 or openings defined by the spokes 24. The insert 28 including the grate 20 can be fixedly mounted within the separation chamber 17 using any suitable fastening device, method or system. For example, the insert 28 can be mounted to an interior of the sidewall 16 using a suitable adhesive or a press fit.


With additional reference to FIG. 3, the valve 18 is illustrated in an open position. In the open position, the cylindrical disk 40 is not perpendicular to the longitudinal axis A of the separation chamber 17, as it is in the open position, but rather its perimeter is flexed downward toward the second end to space the sealing member 34 apart from the grate 20 and permit the passage of materials through the openings 25 between the spokes 24. As further described herein, movement of the cylindrical disk 40 between the closed position of FIG. 2, for example, and the open position of FIG. 3, for example, can be caused by centrifugal force or pressure exerted against the sealing member 34 and the cylindrical disk 40 when the separation chamber 17 is loaded with a multiple component composition and inserted in a centrifuge.


The funnel 52 at the second end 14 of the chamber 17 generally includes a base portion 54 at the longitudinal axis A of the separation chamber 17. Extending from the base portion 54 is an angled cylindrical sidewall 56. The sidewall 56 is angled such that it slopes from the sidewall 16 of the separation chamber 17 toward the base portion 54. Thus, the funnel 52 directs material along the angled cylindrical sidewall 56 toward the base portion 54 where the apertures 48 of the mounting tube 42 are positioned. The funnel 52 can be secured at the second end 14 in any suitable manner, such as with a suitable adhesive or a press fit. The funnel 52 can include a counterbore or recess 55 on its undersurface facing the second end 14 of the device 10. The recess 55 accommodates a dimple 57 at the second end 14 of the device 10. Cooperation between the dimple 57 and the recess 55 can retain the funnel 52 centered in the separation chamber 17. The dimple 57 can cooperate with a corresponding feature in a centrifugation device to properly position the device 10 in the centrifuge.


The separation chamber further includes a loading port 58, a first extraction port 60, and a second extraction port 62. The loading port 58 can be any suitable port that extends into the separation chamber 17 to permit the introduction of materials into the separation chamber 17. As illustrated, the loading port 58 is at the first end 12 and extends there through. The loading port 58 can also be offset from the longitudinal axis A, as illustrated. The loading port 58 can include a loading port cap 64 that can be fastened to the port 58 using any suitable connection, such as a Luer lock connection. The Luer lock connection can also cooperate with a device for delivering the multiple component material to the separation chamber 17, such a syringe.


The first extraction port 60 can be any suitable port that extends into the separation chamber 17 to permit the withdrawal of one or more components of a multiple component material from within the separation chamber 17. As illustrated, the first extraction port 60 is at the first end 12 and extends there through. The first extraction port 60 can include a cap 66 that can be fastened to the first extraction port 60 using any suitable connection, such as a Luer lock connection. The Luer lock connection can also cooperate with a device for withdrawing the components from within the separation chamber 17, such as a syringe. Extending from the first extraction port 60 can be a first extraction tube 68. As illustrated, the first extraction tube 68 extends from the port 60 to a position proximate to a first side 69 of the valve 18 that faces the first end 12. However, one skilled in the art will recognize that the extraction tube 68 can be of any suitable length to extract a desired component of the multiple component composition of a specific density. For example, if the composition includes adipose tissue and purified fat is desired for extraction, then the extraction tube 68 can extend approximately 1.5 inches from the first end 12, such as in applications where 60 ml of adipose tissue is loaded for separation in the separation chamber 17 having a diameter of about 1.35 inches and a volume of about 90 ml. This is because purified fat is typically one of the least dense fractions of adipose tissue. Alternatively, if one or more of the more dense fractions of adipose tissue is desired for extraction, such as oil or excess/tumescent fluid, then the extraction tube 68 can extend from the first end 12 to a distance that is about 0.25 inches from the valve 18. Such a longer extraction tube 68 can also be use to extract purified fat by drawing off the more dense fractions prior to drawing the purified fat.


The second extraction port 62 can be any suitable port that extends into the separation chamber 17 to permit the withdrawal of one or more components of the multiple component material from within the separation chamber 17. As illustrated, the second extraction port 62 is at the first end 12 and extends there through. The second extraction port 62 can include a cap 70 that can be fastened to the second extraction port 62 using any suitable connection, such as a Luer lock connection. The Luer lock connection can also cooperate with a device for withdrawing the components from within the separation chamber 17, such as a syringe.


Extending from the second extraction port 62 can be the second extraction tube 72. As illustrated, the second extraction tube 72 extends from the second extraction port 62 along the longitudinal axis A to the valve 18. At the valve 18, the second extraction tube 72 extends through the center opening 22 of the grate 20, through the opening 38 of the sealing member 34, through the opening 44 of the valve actuation member 36, and the through port 50 to a position proximate to the apertures 48. Thus, the second extraction tube 72 provides fluid communication between the apertures 48 and the second extraction port 62. The second extraction tube 72 can sit on a shoulder 73 of the mounting tube 42 and can be secured within the valve 18, such as within the through port 50, in any suitable manner, such as with a press-fit or a suitable adhesive.


One skilled in the art will appreciate that the grate or screen 20 can be provided in a variety of different configurations in addition to those illustrated. Accordingly and with additional reference to FIG. 5, the grate or screen 20 can include round cutouts 74 in place of the spokes 24. Any other shaped opening or cutout can also be used that will permit passage of select fractions of a multiple component material.


With additional reference to FIGS. 6-9, use of the separation device 10 to separate adipose tissue into different fractions including cellular material, purified fat, and tumescent fluid is described below. This description is for exemplary purposes only because the separation device 10 can be used to separate fractions of a wide variety of different multiple component materials.


With initial reference to FIG. 6, the multiple component composition, such as adipose tissue, is loaded into the separation chamber 17 through the loading port 58. The adipose tissue can be delivered to the separation chamber 17 using any suitable transfer device, such as a syringe 80. The adipose tissue is loaded with the valve 18 in the closed position of FIG. 2. Thus, the adipose tissue will initially be seated atop the valve 18 on the first side 69 of the valve 18 proximate to the first end 12. Any suitable amount of adipose tissue can be used, such as about 60 ml. when a 90 ml. separation chamber having a diameter of 1.35 inches is used.


Prior to being loaded in the separation chamber 17, the adipose tissue, or any multiple component composition, can be optionally subject to mechanical disruption. Mechanical disruption loosens the adipose tissue to facilitate separation of the different fractions during further processing. Any suitable disruptor can be used, such as the disruptors described in U.S. application Ser. No. 12/395,085 titled “A System For Separating A Material,” which was filed on Feb. 27, 2009 and is assigned to Biomet Biologics, LLC., which is incorporated by reference herein. This type of disruptor includes a screen or grate that the multiple component material is forced through to loosen the interaction between the different fractions.


After the adipose tissue is loaded, a suitable anticoagulant, such as citrate phosphate dextrose (“CPD”), can be added as well as through the loading port 58. Any suitable amount of CPD can be added, such as about 8.5 cc for 60 cc of adipose tissue. The separation device 10 can then be incubated at about 37° C. for about five minutes. Any suitable device or method can be used to perform the incubation, such as by placing the separation device 10 in a heat bath or wrapping the device 10 in a heat pack.


The separation device 10 containing the adipose tissue is then spun in a suitable rotational device, such as the centrifuge 90 illustrated in FIG. 7. As illustrated, multiple separation devices 10 can be spun simultaneously. The separation device 10 can be initially spun at about 100 to about 1,500× gravity for about 5 minutes to allow for initial separation of fat layers, including oil, fatty tissue, excess/tumescent fluid, etc. The speed of the centrifuge can then increased to about 1,500 to about 3,000×gravity for about an additional 12-15 minutes. Alternatively, the separation device 10 can be subject to a single centrifugation at about 1,500 to about 3,000×gravity and 3,200 revolutions/minute for about 15 minutes.


During centrifugation, gravitational forces act on the valve 18 to cause the valve 18 to move to the open position of FIG. 3. Specifically and with additional reference to FIG. 8, gravitational forces cause the valve actuation member 36 and the sealing member 34 mounted thereto to bend downward along the longitudinal axis A such that the outer diameter of both the valve actuation member 36 and the sealing member 34 move toward the second end 14. The valve actuation member 36 and the sealing member 34 bend at the portions proximate to the longitudinal axis A to provide a “flap valve.” This separates the sealing member 34 from the grate 20 to create a space therebetween through which components of the multiple component composition, such as cellular material where the multiple component material is adipose tissue, can pass and collect at the base portion 54 of the insert 52, which along with the angled cylindrical sidewall 56 defines a sump on a second side 71 of the valve 18.


With additional reference to FIG. 9, centrifugation causes the different fractions of the multiple component material to separate according to density such that fractions with the greatest density settle at the second end 14. The least dense fractions settle proximate to the first end 12 or most distal to the second end 14. After centrifugation, the valve 18 returns to the closed position, illustrated in, for example, FIG. 9. When closed, the valve 18 separates the multiple component material such that at least one fraction of a first density is separated between the valve 18 and the second end 14, and a second fraction having a second density that is greater than the first density is separated on an opposite side of the valve 18, which is proximate to the first end 12.


The valve 18 is positioned within the separation chamber 17 along the longitudinal axis A such that after centrifugation the two fractions of the multiple component material that are most desirable are separated on opposite sides of the valve 18. One skilled in the art will recognize that the position of the valve 18 along the longitudinal axis A will depend on the densities of the most desired fractions.


For example, when the multiple component material is adipose tissue, the valve can be positioned from about 0.5 inches to about 1.5 inches, such as about 0.75 inches, from the second end 14 in applications where the separation chamber 17 has a diameter of about 1.35 inches and a volume of about 90 ml. As a result, the fractions of adipose tissue of the greatest density, including cellular material 92 having a typical density of about 1.06 g/ml to about 1.1 g/ml, will be isolated proximate to the second end 14 on the second side 71 of the valve 18. Conversely, the fractions of adipose tissue of the least density, including purified fat having a density of about 0.95 g/ml, excess water or other fluid having a density of about 1.0 g/ml, oil, etc. at 94 are isolated on the first side 69 of the valve 18. A tumescent fluid layer 95 will be isolated on both sides of the valve 18 between the cellular material 92 and the purified fat.


To provide higher cell yields, the diameter of the separation chamber 17 can be increased and/or the volume of adipose tissue can be decreased. This increases the surface area of the adipose tissue, thus making it easier for the cells to travel through the fat and extra cellular matrix (ECM) toward the second end 14.


Increased cell yields can also be provided by subjecting the fractions 94 isolated on the first side 69 of the valve 18, such as purified fat, excess fluid, oil, etc., to a second disruption and/or centrifugation process. For example, after the one or more fractions 94 are isolated through centrifugation, the fractions 94 can again be passed through the disruptor 120 to loosen the interaction between the materials and then again be centrifuged in the separation chamber 17 to permit isolation of cellular material 94 on the second side 71 of the valve 18 that was not previously isolated. Both the disruption and centrifugation processes are further described below.


With additional reference to FIG. 9, the isolated fractions can be withdrawn as desired using a suitable extraction device, such as a syringe. For example, the purified fat, excess fluid, oil, etc. 94 can be withdrawn through the first extraction port 60 using a suitable syringe 96. Similarly, the cellular material 92 can be withdrawn through the second extraction port 62, via the aperture 48 and the second extraction tube 72 using a suitable syringe 98. The angled cylindrical sidewall 56 and the base portion 54 act as a sump to direct the cellular material 92 toward the apertures 48 of the distal end 46 of the mounting tube 42 to facilitate withdrawal of the cellular material 92 through the second extraction port 62. Prior to withdrawing the purified fat through the first extraction port 60 and subsequent to withdrawing the cellular material 92 through the second extraction port 62, the tumescent fluid layer 95 can be withdrawn through the first and the second extraction ports 60 and 62.


The isolated fractions can be used for a variety of different purposes. For example, the cellular material 92 can be used to facilitate wound healing, such as by directly injecting the cellular material 92 to a wound site of a patient 100, as illustrated in FIG. 10. The purified fat can be used in a variety of different types of reconstructive and cosmetic surgery, such as facial reconstruction, breast reconstruction, and in most any area in which a fat filling is desired.


With additional reference to FIG. 11, a suction tube 102 with a suitable impingement device attached to an end thereof, such as a cannula 104, can be used to draw the multiple component material directly from a patient into the separation device 10. The end of the suction tube 102 opposite to the cannula 104 can be secured to the loading port 58 using any suitable connection, such as a Luer lock. The cannula 104 can be inserted directly into an area 106 of the patient from where the adipose tissue is desired to be removed.


To facilitate withdrawal of the adipose tissue from the desired area 106 of the patient, a suitable extraction device, such as a vacuum pump 110, can be used. The vacuum pump 110 can be connected to a separate vacuum port 112 at the first end 12 of the separation chamber 17 that provides fluid communication with the interior volume of the separation chamber 17. The vacuum pump 110 can be connected to the vacuum port 112 using a suitable suction tube 108. The vacuum pump 110 can be any suitable vacuum pump 110 operable to withdraw the multiple component material out of the suitable area 106 of the patient to within the separation chamber 17. After the multiple component composition is drawn into the separation chamber 17, the vacuum pump 110 can be disconnected from the vacuum port 112 and the vacuum port 112 can be closed with a suitable cap.


With additional reference to FIG. 12, the separation device 10 can include a suitable disruptor, such as the disruptor 120. The disruptor 120 generally includes a disruptor chamber 122, a plunger 124, a disruptor inlet port 126, a disruptor vacuum port 128, a disruption screen 130, and a disruptor outlet port 132.


The disruptor inlet port 126 provides fluid communication between an exterior of the disruptor 120 and the disruptor chamber 122. The suction tube 102 with the cannula 104 attached thereto can be connected to the disruptor inlet port 126 using any suitable connection, such as a Luer lock connection.


The disruptor vacuum port 128 also provides fluid communication between an exterior of the disruptor 120 and the disruptor chamber 122. The vacuum pump 110 can be connected to the disruptor vacuum port 128 using any suitable connection, such as a Luer lock connection, to draw the multiple component composition into the disruptor chamber 122.


After a suitable amount of the multiple component material, such as adipose tissue, is drawn into the chamber 122, the pump 110 can be stopped and the plunger 124 can be depressed to drive the multiple component material through the disruption screen 130, which is also illustrated in FIG. 13. The disruption screen 130 can be any suitable disruption screen known in the art, such as those described in U.S. application Ser. No. 12/395,085 incorporated by reference herein. As illustrated, the disruption screen 130 includes a plurality of round openings 131, however any suitably shaped openings or grated surface can be provided to disrupt a material to be passed therethrough. As the material is pushed through the disruption screen, it is softened and its fractions are loosened to facilitate separation of the fractions during the centrifugation process.


The disruptor outlet port 132 is connected to an inlet port 134 of the separation device 10. As illustrated, the inlet port 134 extends through the first end 12 and is similar to the loading port 58. The inlet port 134 can be connected to the disruptor outlet port 132 in any suitable manner, such as through a Luer lock connection, to provide fluid communication between the disruptor chamber 122 and the interior volume of the separation chamber 17. Thus, as the plunger 124 is depressed, the multiple component composition is pushed through the disruptor screen 130 and into the interior volume of the separation chamber 17 where it is separated into its different fractions through centrifugation as described above. The separate inlet port 134 for the disruptor 120 is optional as the disruptor 120 can also be connected to the loading port 58.


The inlet port 134 can be located at the axial center A of the first end 12 to facilitate introduction of the adipose tissue into the separation chamber 17, however, the inlet port 134 can be located at any suitable location and can be eliminated altogether because the disruptor 120 can also be connected to the loading port 58. When the inlet port 134 is located at the axial center A, the second extraction port 62 can be moved offset from the axial center A. Accordingly, the second extraction tube 72 does not extend entirely along the axial center A as described above, but can be offset with an elbow portion 136. The inlet port 134 can be in addition to, or can take the place of, the loading port 58.


While the disruptor screen 130 is illustrated as being integral with the disruptor 120, the disruptor screen 130 can also be a separate component that is connected to both the disruptor inlet port 126 and the disruptor 120 using suitable fastening devices, such as Luer lock connections. Further, the disruptor screen 130 can be integral with the separation device 10 and the disruptor 120 can be connected to the disruptor screen 130 with a suitable connection.


While the disruptor 120 is illustrated as being connected to a single separation device 10, the disruptor 120 can be connected to multiple separation devices 10 through the use of a suitable connection device, such as a branch connector, that will provide fluid communication between the disruptor 120 and inlet ports of multiple separation chambers.


The present teachings further provide for a sterile method of using the separation device 10. With reference to FIGS. 11 and 12, the cannula 104 and the suction tube 102 can be sterilized and passed into a sterile field where the cannula 104 can be connected to a first end of the suction tube 102. A second end of the suction tube 102 can be connected to either the loading port 58 of the separation device 10 (FIG. 11) or the disruptor inlet port 126 of the disruptor 120 (FIG. 12). The separation device 10 and the disruptor 120 may be inside or outside of the sterile field depending on the procedure. The suction tube 108 is then connected to the vacuum pump 110, which is outside of the sterile field, and either the first extraction port 60 (FIG. 11) or the disruptor vacuum port 128 (FIG. 12). Thus, the separation device 10 need not ever enter the sterile field, thus allowing it to be handled by non-sterile personnel for processing in the centrifuge 90. Use of the device 10 outside of the sterile field is advantageous because it frees up space in the sterile area. Use of the device 10 inside of the sterile area decreases the possibility of contamination.


To facilitate collection of the multiple component composition, multiple cannulas 104 can be inserted into area 106 of the patient from where the composition is to be removed and multiple suction tubes 102 can be connected to the cannulas 104. The suction tubes 102 can then be connected to the loading port 58 or the disruptor inlet port 126 using a suitable connecting device, such as a suitable branch connector. Also, multiple vacuum pumps 110 can be used to increase the vacuum force. The pumps 110 can be connected to the first extraction port 60 or the disruptor vacuum port 128 using multiple suction tubes 108 connected by, for example, a branch line.


The foregoing description of the embodiments has been provided for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention. Individual elements or features of a particular embodiment are generally not limited to that particular embodiment, but, where applicable, are interchangeable and can be used in a selected embodiment, even if not specifically shown or described. The same may also be varied in many ways. Such variations are not to be regarded as a departure from the invention, and all such modifications are intended to be included within the scope of the invention.

Claims
  • 1. A method for isolating at least two fractions of a multiple component material comprising: loading the multiple component material into a separation chamber of a separation device between a valve mounted at a fixed position in the separation chamber and a first end of the device, the first end is opposite to a second end and a sidewall extends between the first end and the second end to define the separation chamber having an interior volume wherein the valve includes a screen, a valve activation member, and a seal, and wherein each of the screen, the valve activation member, and the seal define a through hole at an axial center thereof; wherein the through hole is in fluid communication with apertures at an end of the valve activation member proximate to the second end; and wherein an extraction tube is seated in the through hole and is connected to an extraction port of the separation device;centrifuging the separation device such that the valve moves to an open position in response to gravitational forces exerted on the device to permit a first fraction of the multiple component material of a first density to pass through the valve toward the second end;ceasing centrifugation of the separation device to permit the valve to move to a closed position, thus isolating the first fraction of the first density between the valve and the second end and isolating a second fraction of a second density that is less dense than the first density between the valve and the first end; andwithdrawing at least one of the first fraction and the second fraction from the separation chamber for use in a subsequent procedure.
  • 2. The method of claim 1, further comprising wherein the multiple component material is adipose tissue, and loading the adipose tissue into the separation chamber to isolate the first fraction including cellular material, the second fraction including purified fat, and a third fraction including tumescent fluid; incubating the separation device with the adipose tissue loaded therein for about five minutes at about 37° C.; andwherein the step of centrifuging the separation device is carried out at a speed of about 3,200 revolutions/minute for about fifteen minutes.
  • 3. The method of claim 1, further comprising extracting the multiple component material from a patient and simultaneously loading the material directly into the separation device using a vacuum pump.
  • 4. The method of claim 3, wherein extracting comprises inserting multiple cannulas into an area of the patient, wherein each cannula is fluidly connected to a suction tube, and the suction tubes are fluidly connected to the separation device with a branch connector, and activating the vacuum pump to draw the multiple component material form the patient, through each cannula, and into the separation chamber.
  • 5. The method of claim 1, further comprising subjecting the multiple component material to disruption prior to loading the multiple component material into the separation chamber.
  • 6. The method of claim 1, further comprising using a vacuum pump to load the multiple component material from a patient into a disruptor comprising a plunger and a screen and depressing the plunger to drive the multiple component material through the screen and into the separation chamber.
  • 7. The method of claim 1, wherein centrifuging comprises spinning at a force of about 100×g to about 1500×g for about 5 minutes and increasing the force to about 1500×g to about 3000×g for about an additional 12-15 minutes.
  • 8. The method of claim of claim 1, further comprising adding an anticoagulant to the multiple component material within the separation chamber.
  • 9. The method of claim 1, further comprising wherein the second fraction of the multiple component material includes cells and wherein a cell yield can be increased by withdrawing the second fraction from the separation chamber, passing the second fraction through a disruptor, injecting the second fraction back into the separation device and repeating the steps of centrifuging, ceasing, and withdrawing.
  • 10. The method of claim 1, wherein the method is performed in a sterile field.
  • 11. A method for isolating at least two fractions from adipose tissue comprising: loading the adipose tissue into a separation chamber of a separation device between a valve mounted at a fixed position in the separation chamber and a first end of the device, the first end is opposite to a second end and a sidewall extends between the first end and the second end to define the separation chamber having an interior volume, wherein the valve includes a screen, a valve activation member, and a seal, and wherein each of the screen, the valve activation member, and the seal define a through hole at an axial center thereof, wherein the through hole is in fluid communication with apertures at an end of the valve activation member proximate to the second end, and wherein an extraction tube is seated in the through hole and is connected to an extraction portion of the separation device;centrifuging the separation device at about 1500×g to about 3000×g for about 15 minutes such that the valve moves to an open position in response to gravitational forces exerted on the device to permit a first dense fraction of the adipose tissue comprising cellular material to pass through the valve toward the second end;ceasing centrifugation of the separation device to permit the valve to move to a closed position, thus isolating the first dense fraction between the valve and the second end and isolating a second less dense fraction comprising purified fat between the valve and the first end, wherein a tumescent fluid layer is isolated on both sides of the valve; andwithdrawing at least one of the cellular material and the purified fat from the separation chamber for use in a subsequent procedure.
  • 12. The method of claim 11, further comprising adding citrate phosphate dextrose to the adipose tissue within the separation chamber and incubating at 37° C. for about 5 minutes prior to centrifuging.
  • 13. The method of claim 11, further comprising performing an initial centrifugation at about 100×g to about 1500×g for about 5 minutes to allow for initial separation of fat layers prior to increasing the g force to about 1500×g to about 3000×g.
  • 14. The method of claim 11, further comprising loosening the interaction between materials of the adipose tissue by passing the adipose tissue through a disruptor prior to loading the adipose tissue into the separation chamber.
  • 15. The method of claim 14, wherein the adipose tissue is drawn directly from the patient through a tube and into the disruptor by using a vacuum pump.
  • 16. The method of claim 11, further comprising extracting the adipose tissue from a patient and simultaneously loading the adipose tissue directly into the separation device using a vacuum pump.
  • 17. A method for isolating at least two fractions from adipose tissue comprising: extracting adipose tissue from the patient and simultaneously loading the tissue directly into a separation device using a vacuum pump, wherein the adipose tissue is loaded into a separation chamber of the separation device between a valve mounted at a fixed position in the separation chamber and a first end of the device, the first end is opposite to a second end and a sidewall extends between the first end and the second end to define the separation chamber having an interior volume wherein the valve includes a screen, a valve activation member, and a seal, and wherein each of the screen, the valve activation member, and the seal define a through hole at an axial center thereof; wherein the through hole is in fluid communication with apertures at an end of the valve activation member proximate to the second end; and wherein an extraction tube is seated in the through hole and is connected to an extraction port of the separation device;centrifuging the separation device such that the valve moves to an open position in response to gravitational forces exerted on the device to permit a first dense fraction of the adipose tissue comprising cellular material to pass through the valve toward the second end;ceasing centrifugation of the separation device to permit the valve to move to a closed position, thus isolating the first dense fraction between the valve and the second end and isolating a second less dense fraction comprising purified fat between the valve and the first end, wherein a tumescent fluid layer is isolated on both sides of the valve;withdrawing at least one of the cellular material and the purified fat from the separation chamber; andadministering the cellular material or the purified fat to the patient.
  • 18. The method of claim 17, wherein centrifuging comprises spinning the separation device at about 1500×g to about 3000×g for about 15 minutes.
  • 19. The method of claim 17, wherein the cellular material is administered to the patient to facilitate wound healing.
  • 20. The method of claim 17, wherein the purified fat is administered to the patient during reconstructive or cosmetic surgery.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 12/758,127 filed Apr. 12, 2010. The entire disclosure of the above application is incorporated herein by reference.

US Referenced Citations (566)
Number Name Date Kind
280820 Hickson et al. Jul 1883 A
593333 Park Nov 1897 A
1468313 Lux Sep 1923 A
1593814 Vogel Jul 1926 A
2722257 Lockhart Nov 1955 A
3013557 Pallotta Dec 1961 A
3141846 Laven, Jr. Jul 1964 A
3159159 Cohen Dec 1964 A
3300051 Mitchell Jan 1967 A
3409165 Creith Nov 1968 A
3420374 Umeda Jan 1969 A
3441143 Kudlaty Apr 1969 A
3453364 Flodin et al. Jul 1969 A
3469369 Helmke Sep 1969 A
3508653 Coleman Apr 1970 A
3545671 Ross Dec 1970 A
3583627 Wilson Jun 1971 A
3596652 Winkelman Aug 1971 A
3647070 Adler Mar 1972 A
3654925 Holderith Apr 1972 A
3661265 Greenspan May 1972 A
3706305 Berger et al. Dec 1972 A
3706306 Berger et al. Dec 1972 A
3723244 Breillatt, Jr. Mar 1973 A
3741400 Dick Jun 1973 A
3779383 Ayres Dec 1973 A
3785549 Latham, Jr. Jan 1974 A
3814248 Lawhead Jun 1974 A
3849072 Ayres Nov 1974 A
3850369 Bull et al. Nov 1974 A
3879295 Glover et al. Apr 1975 A
3887466 Ayres Jun 1975 A
3894952 Ayres Jul 1975 A
3896733 Rosenberg Jul 1975 A
3897337 Ayres Jul 1975 A
3897343 Ayres Jul 1975 A
3909419 Ayres Sep 1975 A
3929646 Adler Dec 1975 A
3931010 Ayres et al. Jan 1976 A
3931018 North, Jr. Jan 1976 A
3935113 Ayres Jan 1976 A
3937211 Merten Feb 1976 A
3941699 Ayres Mar 1976 A
3945928 Ayres Mar 1976 A
3951801 Ayres Apr 1976 A
3957654 Ayres May 1976 A
3962085 Liston et al. Jun 1976 A
3965889 Sachs Jun 1976 A
3972812 Gresl, Jr. Aug 1976 A
3982691 Schlutz Sep 1976 A
4001122 Griffin Jan 1977 A
4020831 Adler May 1977 A
4046699 Zine, Jr. Sep 1977 A
4055501 Cornell Oct 1977 A
4059108 Latham, Jr. Nov 1977 A
4066549 Oeser et al. Jan 1978 A
4077396 Wardlaw et al. Mar 1978 A
4088582 Murty et al. May 1978 A
4146172 Cullis et al. Mar 1979 A
4152270 Cornell May 1979 A
4154690 Ballies May 1979 A
4159896 Levine et al. Jul 1979 A
4187979 Cullis et al. Feb 1980 A
4189385 Greenspan Feb 1980 A
4203840 Stoeppler et al. May 1980 A
4204537 Latham, Jr. May 1980 A
4225580 Rothman et al. Sep 1980 A
4229298 Bange Oct 1980 A
4269718 Persidsky May 1981 A
4294707 Ikeda et al. Oct 1981 A
4298598 Schwarz et al. Nov 1981 A
4300717 Latham, Jr. Nov 1981 A
4303193 Latham, Jr. Dec 1981 A
4314823 Rich, Jr. et al. Feb 1982 A
4322298 Persidsky Mar 1982 A
4332351 Kellogg et al. Jun 1982 A
4362567 Schwarz et al. Dec 1982 A
4364832 Ballies et al. Dec 1982 A
4377572 Schwarz et al. Mar 1983 A
4379849 Heimreid Apr 1983 A
4411794 Schwinn et al. Oct 1983 A
4414976 Schwarz et al. Nov 1983 A
4416654 Schoendorfer et al. Nov 1983 A
4417981 Nugent Nov 1983 A
4424132 Iriguchi et al. Jan 1984 A
4427650 Stroetmann et al. Jan 1984 A
4427651 Stroetmann et al. Jan 1984 A
4442655 Stroetmann et al. Apr 1984 A
4443345 Wells Apr 1984 A
4445550 Davis et al. May 1984 A
4446021 Aufderhaar et al. May 1984 A
4453927 Sinko Jun 1984 A
4453939 Zimmerman et al. Jun 1984 A
4464167 Schoendorfer et al. Aug 1984 A
4511662 Baran et al. Apr 1985 A
4537767 Rothman et al. Aug 1985 A
RE32089 Blatt et al. Mar 1986 E
4577514 Bradley et al. Mar 1986 A
4610656 Mortensen Sep 1986 A
4617009 Ohlin et al. Oct 1986 A
4627879 Rose et al. Dec 1986 A
4631055 Redl et al. Dec 1986 A
4632761 Bowers et al. Dec 1986 A
4639316 Eldegheidy Jan 1987 A
4650678 Fuhge et al. Mar 1987 A
4655211 Sakamoto et al. Apr 1987 A
4672969 Dew Jun 1987 A
4675117 Neumann et al. Jun 1987 A
4680025 Kruger et al. Jul 1987 A
4714457 Alterbaum Dec 1987 A
4722790 Cawley et al. Feb 1988 A
4724317 Brown et al. Feb 1988 A
4735616 Eibl et al. Apr 1988 A
4735726 Duggins Apr 1988 A
4738655 Brimhall et al. Apr 1988 A
4755300 Fischel et al. Jul 1988 A
4755301 Bowers Jul 1988 A
4770779 Ichikawa et al. Sep 1988 A
4776964 Schoendorfer et al. Oct 1988 A
4818291 Iwatsuki et al. Apr 1989 A
4818386 Burns Apr 1989 A
4828710 Itoh et al. May 1989 A
4832851 Bowers et al. May 1989 A
4834890 Brown et al. May 1989 A
4839058 Cawley et al. Jun 1989 A
4844818 Smith Jul 1989 A
4846780 Galloway et al. Jul 1989 A
4846835 Grande Jul 1989 A
4850952 Figdor et al. Jul 1989 A
4853137 Ersson et al. Aug 1989 A
4871462 Fischel et al. Oct 1989 A
4874368 Miller et al. Oct 1989 A
4877520 Burns Oct 1989 A
4879031 Panzani et al. Nov 1989 A
4900453 Sedlmayer et al. Feb 1990 A
4902281 Avoy Feb 1990 A
4909251 Seelich et al. Mar 1990 A
4915847 Dillon et al. Apr 1990 A
4917801 Luderer et al. Apr 1990 A
4928603 Rose et al. May 1990 A
4929242 Desecki et al. May 1990 A
4933291 Daiss et al. Jun 1990 A
4939081 Figdor et al. Jul 1990 A
4943273 Pages et al. Jul 1990 A
4946601 Fiehler Aug 1990 A
4950220 Wells et al. Aug 1990 A
4957637 Cornell Sep 1990 A
4957638 Smith Sep 1990 A
4973168 Chan Nov 1990 A
4983157 Pober et al. Jan 1991 A
4983158 Headley Jan 1991 A
4985153 Kuroda et al. Jan 1991 A
5000970 Shanbhag et al. Mar 1991 A
5002571 O'Donnell, Jr. et al. Mar 1991 A
5019243 McEwen et al. May 1991 A
5024613 Vasconcellos et al. Jun 1991 A
5030215 Morse et al. Jul 1991 A
5030341 McEwen et al. Jul 1991 A
5039401 Columbus et al. Aug 1991 A
5045048 Kaleskas et al. Sep 1991 A
5047004 Wells Sep 1991 A
5053127 Schoendorfer et al. Oct 1991 A
5053134 Luderer et al. Oct 1991 A
5071570 Shiraki et al. Dec 1991 A
5080262 Herold et al. Jan 1992 A
5086784 Levine et al. Feb 1992 A
5100564 Pall et al. Mar 1992 A
5104375 Wolf et al. Apr 1992 A
5112484 Zuk, Jr. May 1992 A
5112490 Turpen May 1992 A
5131907 Williams et al. Jul 1992 A
5137832 Levine et al. Aug 1992 A
5141645 Shiraki et al. Aug 1992 A
5147290 Jonsson et al. Sep 1992 A
5152905 Pall et al. Oct 1992 A
5156613 Sawyer Oct 1992 A
5165938 Knighton Nov 1992 A
5171456 Hwang et al. Dec 1992 A
5173295 Wehling et al. Dec 1992 A
5178602 Wells Jan 1993 A
5185001 Galanakis Feb 1993 A
5188583 Guigan et al. Feb 1993 A
5190057 Sarfarazi Mar 1993 A
5190759 Lindblad et al. Mar 1993 A
5197985 Caplan et al. Mar 1993 A
5203825 Haynes et al. Apr 1993 A
5204537 Bennet et al. Apr 1993 A
5206023 Hunziker et al. Apr 1993 A
5207638 Choksi et al. May 1993 A
5217426 Bacehowski et al. Jun 1993 A
5217627 Pall et al. Jun 1993 A
5219328 Morse et al. Jun 1993 A
5226877 Epstein Jul 1993 A
5226914 Caplan et al. Jul 1993 A
5234608 Duff Aug 1993 A
5236604 Fiehler Aug 1993 A
5251786 Sarrine Oct 1993 A
5258126 Pall et al. Nov 1993 A
5260420 Burnouf-Radosevich et al. Nov 1993 A
5269927 Fiehler Dec 1993 A
5271852 Luoma, II Dec 1993 A
5279825 Wehling et al. Jan 1994 A
5281342 Biesel et al. Jan 1994 A
5290552 Sierra et al. Mar 1994 A
5290918 Bui-Khac et al. Mar 1994 A
5298171 Biesel et al. Mar 1994 A
5304372 Michalski et al. Apr 1994 A
5316674 Pall et al. May 1994 A
5318524 Morse et al. Jun 1994 A
5318782 Weis-Fogh et al. Jun 1994 A
5321126 van Dommelen et al. Jun 1994 A
5322620 Brown et al. Jun 1994 A
5330974 Pines et al. Jul 1994 A
5344752 Murphy Sep 1994 A
5354483 Furse Oct 1994 A
5370221 Magnusson et al. Dec 1994 A
5370802 Brown Dec 1994 A
5372945 Alchas et al. Dec 1994 A
5376263 Fischel Dec 1994 A
5387187 Fell et al. Feb 1995 A
5393674 Levine et al. Feb 1995 A
5395923 Bui-Khac et al. Mar 1995 A
5403272 Deniega et al. Apr 1995 A
5405607 Epstein Apr 1995 A
5409833 Hu et al. Apr 1995 A
5411885 Marx May 1995 A
5417650 Gordon May 1995 A
5420250 Lontz May 1995 A
5443481 Lee Aug 1995 A
5454958 Fiehler Oct 1995 A
5456693 Conston et al. Oct 1995 A
5456885 Coleman et al. Oct 1995 A
5474687 Van Vlasselaer Dec 1995 A
5480378 Weis-Fogh et al. Jan 1996 A
5484383 Fitch, Jr. et al. Jan 1996 A
5486359 Caplan et al. Jan 1996 A
5494578 Brown et al. Feb 1996 A
5494592 Latham, Jr. et al. Feb 1996 A
5501371 Schwartz-Feldman Mar 1996 A
5505685 Antwiler Apr 1996 A
5510102 Cochrum Apr 1996 A
5520885 Coelho et al. May 1996 A
5525477 Hassouna Jun 1996 A
5533518 Vogler Jul 1996 A
5560830 Coleman et al. Oct 1996 A
5575778 Hardt et al. Nov 1996 A
5577513 Van Vlasselaer Nov 1996 A
5585007 Antanavich et al. Dec 1996 A
5588958 Cunningham et al. Dec 1996 A
5589462 Patat et al. Dec 1996 A
5601711 Sklar et al. Feb 1997 A
5601727 Bormann et al. Feb 1997 A
5603845 Holm Feb 1997 A
5607579 Latham, Jr. et al. Mar 1997 A
5614106 Payrat et al. Mar 1997 A
5618663 Delmas et al. Apr 1997 A
5632895 Tsukagoshi et al. May 1997 A
5632905 Haynes May 1997 A
5641414 Brown Jun 1997 A
5641622 Lake et al. Jun 1997 A
5643192 Hirsh et al. Jul 1997 A
5643193 Papillon et al. Jul 1997 A
5645540 Henniges et al. Jul 1997 A
5646004 Van Vlasselaer Jul 1997 A
5648223 Van Vlasselaer Jul 1997 A
5649903 Deniega et al. Jul 1997 A
5663051 Vlasselaer Sep 1997 A
5674173 Hlavinka et al. Oct 1997 A
5707331 Wells et al. Jan 1998 A
5707647 Dunn et al. Jan 1998 A
5707876 Levine Jan 1998 A
5716616 Prockop et al. Feb 1998 A
5723331 Tubo et al. Mar 1998 A
5724988 Dennehey et al. Mar 1998 A
5733466 Benebo et al. Mar 1998 A
5733545 Hood, III Mar 1998 A
5736033 Coleman et al. Apr 1998 A
5738784 Holm et al. Apr 1998 A
5738796 Bormann et al. Apr 1998 A
5750025 Holmes et al. May 1998 A
5750658 Coelho et al. May 1998 A
5762798 Wenthold et al. Jun 1998 A
5785700 Olson Jul 1998 A
5786217 Tubo et al. Jul 1998 A
5788662 Antanavich et al. Aug 1998 A
5792344 Holm Aug 1998 A
5795489 Holm et al. Aug 1998 A
5795571 Cederholm-Williams et al. Aug 1998 A
5795751 Apel Aug 1998 A
5811094 Caplan et al. Sep 1998 A
5811151 Hendriks et al. Sep 1998 A
5817519 Zelmanovic et al. Oct 1998 A
5823986 Peterson Oct 1998 A
5824084 Muschler Oct 1998 A
5830359 Knight et al. Nov 1998 A
5833866 Brown Nov 1998 A
5834418 Brazeau et al. Nov 1998 A
5837150 Langley et al. Nov 1998 A
5840502 Van Vlasselaer Nov 1998 A
5853600 McNeal et al. Dec 1998 A
5860937 Cohen Jan 1999 A
5863892 Stern et al. Jan 1999 A
5865785 Bischof Feb 1999 A
5885239 Headley et al. Mar 1999 A
5889584 Wardlaw Mar 1999 A
5895346 Wells et al. Apr 1999 A
5899874 Jonsson et al. May 1999 A
5900245 Sawhney et al. May 1999 A
5906934 Grande et al. May 1999 A
5916557 Berlowitz-Tarrant et al. Jun 1999 A
5916743 Lake et al. Jun 1999 A
5918622 Perez et al. Jul 1999 A
5924972 Turvaville et al. Jul 1999 A
5934803 Hutter Aug 1999 A
5938621 Kelly et al. Aug 1999 A
5951160 Ronk Sep 1999 A
5955032 Kelly et al. Sep 1999 A
5955436 Kunkle, Jr. Sep 1999 A
5958250 Brown et al. Sep 1999 A
5958253 Holm et al. Sep 1999 A
5961210 McCardel et al. Oct 1999 A
5980734 Itoh et al. Nov 1999 A
5980757 Brown et al. Nov 1999 A
5985315 Patat et al. Nov 1999 A
5997544 Nies et al. Dec 1999 A
6007811 Sawyer et al. Dec 1999 A
6010627 Hood, III Jan 2000 A
6011490 Tonnesen et al. Jan 2000 A
6020196 Hu et al. Feb 2000 A
6022306 Dumont et al. Feb 2000 A
6025201 Zelmanovic et al. Feb 2000 A
6027655 Holm Feb 2000 A
6049026 Muschler Apr 2000 A
6051146 Green et al. Apr 2000 A
6051147 Bischof Apr 2000 A
6053856 Hlavinka Apr 2000 A
6054122 MacPhee et al. Apr 2000 A
6063297 Antanavich et al. May 2000 A
6063624 Kandler et al. May 2000 A
6071421 Brown Jun 2000 A
6071422 Hlavinka et al. Jun 2000 A
6071423 Brown et al. Jun 2000 A
6090793 Zimmermann et al. Jul 2000 A
6096309 Prior et al. Aug 2000 A
6102843 Kelley et al. Aug 2000 A
6117425 MacPhee et al. Sep 2000 A
6123655 Fell et al. Sep 2000 A
6150163 McPherson et al. Nov 2000 A
6153113 Goodrich et al. Nov 2000 A
6183737 Zaleske et al. Feb 2001 B1
6196987 Holmes et al. Mar 2001 B1
6197325 MacPhee et al. Mar 2001 B1
6200287 Keller et al. Mar 2001 B1
6200606 Peterson et al. Mar 2001 B1
6214338 Antanavich et al. Apr 2001 B1
6221315 Giesler et al. Apr 2001 B1
6245900 Yamasaki et al. Jun 2001 B1
6264890 Boehringer et al. Jul 2001 B1
6274090 Coelho et al. Aug 2001 B1
6277961 Hock et al. Aug 2001 B1
6280400 Niermann Aug 2001 B1
6286670 Smith Sep 2001 B1
6296602 Headley Oct 2001 B1
6316247 Katz et al. Nov 2001 B1
6322785 Landesberg et al. Nov 2001 B1
6327491 Franklin et al. Dec 2001 B1
6328765 Hardwick et al. Dec 2001 B1
6334842 Hlavinka et al. Jan 2002 B1
6342157 Hood, III Jan 2002 B1
6351659 Vilsmeier Feb 2002 B1
6355239 Bruder et al. Mar 2002 B1
6368298 Beretta et al. Apr 2002 B1
6368498 Guilmette Apr 2002 B1
6398972 Blasetti et al. Jun 2002 B1
6406671 DiCesare et al. Jun 2002 B1
6409528 Bodnar Jun 2002 B1
6410344 Chung et al. Jun 2002 B1
6417004 Brady et al. Jul 2002 B1
6440444 Boyce et al. Aug 2002 B2
6444228 Baugh et al. Sep 2002 B1
6464624 Pages Oct 2002 B2
6471069 Lin et al. Oct 2002 B2
6472162 Coelho et al. Oct 2002 B1
6487992 Hollis Dec 2002 B1
6508778 Verkaart et al. Jan 2003 B1
6516953 DiCesare et al. Feb 2003 B1
6523698 Dennehey et al. Feb 2003 B1
6544162 Van Wie et al. Apr 2003 B1
6544727 Hei Apr 2003 B1
6558341 Swisher May 2003 B1
6563953 Lin et al. May 2003 B2
6596180 Baugh et al. Jul 2003 B2
6623959 Harris Sep 2003 B2
6629919 Egozy et al. Oct 2003 B2
6638503 Chitte et al. Oct 2003 B2
6676629 Andrew et al. Jan 2004 B2
6716187 Jorgensen et al. Apr 2004 B1
6719901 Dolecek et al. Apr 2004 B2
6733471 Ericson et al. May 2004 B1
6758978 Bedell Jul 2004 B1
6764531 Hogan Jul 2004 B2
6777231 Katz et al. Aug 2004 B1
6803022 DiCesare et al. Oct 2004 B2
6811777 Mishra Nov 2004 B2
6830762 Baugh et al. Dec 2004 B2
6835353 Smith et al. Dec 2004 B2
6835377 Goldberg et al. Dec 2004 B2
RE38730 Wells et al. Apr 2005 E
6899813 Dolecek et al. May 2005 B2
6905612 Dorian et al. Jun 2005 B2
6911202 Amir et al. Jun 2005 B2
RE38757 Wells et al. Jul 2005 E
6979307 Beretta et al. Dec 2005 B2
7011644 Andrew et al. Mar 2006 B1
7077273 Ellsworth et al. Jul 2006 B2
7077827 Greenfield Jul 2006 B2
7155288 Soykan et al. Dec 2006 B2
7179391 Leach et al. Feb 2007 B2
7195606 Ballin Mar 2007 B2
7223346 Dorian et al. May 2007 B2
7273886 Olivero et al. Sep 2007 B2
7354515 Coull et al. Apr 2008 B2
7374678 Leach et al. May 2008 B2
7411006 Shanbrom Aug 2008 B2
7470371 Dorian et al. Dec 2008 B2
7531355 Rodriguez et al. May 2009 B2
7553413 Dorian et al. Jun 2009 B2
7694828 Swift et al. Apr 2010 B2
7780860 Higgins et al. Aug 2010 B2
7806276 Leach et al. Oct 2010 B2
7832566 Leach et al. Nov 2010 B2
7837884 Dorian et al. Nov 2010 B2
7845499 Higgins et al. Dec 2010 B2
7901584 Dorian et al. Mar 2011 B2
7914689 Higgins et al. Mar 2011 B2
7954646 Leach et al. Jun 2011 B2
7987995 Dorian et al. Aug 2011 B2
7992725 Leach et al. Aug 2011 B2
8048321 Leach et al. Nov 2011 B2
8062534 Higgins et al. Nov 2011 B2
8067534 Jagota et al. Nov 2011 B2
8119013 Leach et al. Feb 2012 B2
8163184 Leach et al. Apr 2012 B2
8187477 Dorian et al. May 2012 B2
8313954 Leach et al. Nov 2012 B2
8328024 Leach et al. Dec 2012 B2
8337711 Dorian et al. Dec 2012 B2
8474630 Dorian et al. Jul 2013 B2
8567609 Landrigan et al. Oct 2013 B2
8591391 Chavarria et al. Nov 2013 B2
8596470 Leach et al. Dec 2013 B2
8783470 Hecker et al. Jul 2014 B2
8801586 Dorian et al. Aug 2014 B2
8808551 Leach et al. Aug 2014 B2
8950586 Dorian et al. Feb 2015 B2
8992862 Leach et al. Mar 2015 B2
9011800 Leach et al. Apr 2015 B2
20010009757 Bischof et al. Jul 2001 A1
20020032112 Pages Mar 2002 A1
20020035820 Farris Mar 2002 A1
20020076400 Katz et al. Jun 2002 A1
20020082220 Hoemann et al. Jun 2002 A1
20020090711 Karlsson Jul 2002 A1
20020104808 Blasetti et al. Aug 2002 A1
20020114775 Pathak Aug 2002 A1
20020161449 Muschler Oct 2002 A1
20020169408 Beretta et al. Nov 2002 A1
20020172666 Sacchi et al. Nov 2002 A1
20020182664 Dolecek et al. Dec 2002 A1
20020192632 Hei et al. Dec 2002 A1
20030033021 Plouhar et al. Feb 2003 A1
20030033022 Plouhar et al. Feb 2003 A1
20030050709 Noth et al. Mar 2003 A1
20030050710 Petersen et al. Mar 2003 A1
20030082152 Hedrick et al. May 2003 A1
20030185803 Kadiyala et al. Oct 2003 A1
20030191429 Andrew et al. Oct 2003 A1
20030205538 Dorian et al. Nov 2003 A1
20040005246 Efthimiadis et al. Jan 2004 A1
20040013575 Stevens et al. Jan 2004 A1
20040120942 McGinnis et al. Jun 2004 A1
20040171146 Katz et al. Sep 2004 A1
20040182395 Brookman Sep 2004 A1
20040182788 Dorian et al. Sep 2004 A1
20040182795 Dorian et al. Sep 2004 A1
20040251217 Leach et al. Dec 2004 A1
20050076396 Katz et al. Apr 2005 A1
20050084961 Hedrick et al. Apr 2005 A1
20050084962 Simon Apr 2005 A1
20050109716 Leach et al. May 2005 A1
20050130301 McKay et al. Jun 2005 A1
20050145187 Gray Jul 2005 A1
20050153441 Hedrick et al. Jul 2005 A1
20050153442 Katz et al. Jul 2005 A1
20050186120 Dorian et al. Aug 2005 A1
20050196393 Shanbrom Sep 2005 A1
20050196874 Dorian et al. Sep 2005 A1
20050247715 Ellsworth et al. Nov 2005 A1
20050260174 Fraser et al. Nov 2005 A1
20050260175 Hedrick et al. Nov 2005 A1
20050282275 Katz et al. Dec 2005 A1
20060051865 Higgins et al. Mar 2006 A1
20060057693 Simon Mar 2006 A1
20060083720 Fraser et al. Apr 2006 A1
20060140923 Evangelista et al. Jun 2006 A1
20060151384 Ellsworth et al. Jul 2006 A1
20060175242 Dorian et al. Aug 2006 A1
20060175244 Dorian et al. Aug 2006 A1
20060178610 Nowakowski Aug 2006 A1
20060196885 Leach et al. Sep 2006 A1
20060243676 Swift et al. Nov 2006 A1
20060273049 Leach et al. Dec 2006 A1
20060273050 Higgins et al. Dec 2006 A1
20060278588 Woodell-May Dec 2006 A1
20070034579 Dorian et al. Feb 2007 A1
20070036768 Fraser et al. Feb 2007 A1
20070075016 Leach Apr 2007 A1
20070208321 Leach et al. Sep 2007 A1
20080011684 Dorian et al. Jan 2008 A1
20080164204 Hatamian et al. Jul 2008 A1
20080173593 Coull et al. Jul 2008 A1
20080193424 McKale et al. Aug 2008 A1
20080210645 Coull et al. Sep 2008 A1
20080217263 Higgins et al. Sep 2008 A1
20080217264 Leach et al. Sep 2008 A1
20080217265 Leach et al. Sep 2008 A1
20080268064 Woodell-May Oct 2008 A1
20080269762 Simon et al. Oct 2008 A1
20080283474 Leach et al. Nov 2008 A1
20080306431 Yoo Dec 2008 A1
20080318317 Roche et al. Dec 2008 A1
20090014391 Leach et al. Jan 2009 A1
20090018313 Shanbrom Jan 2009 A1
20090101599 Dorian et al. Apr 2009 A1
20090131827 Crocker et al. May 2009 A1
20090192528 Higgins et al. Jul 2009 A1
20090220482 Higgins et al. Sep 2009 A1
20090221075 Dorian et al. Sep 2009 A1
20090236297 Dorian et al. Sep 2009 A1
20090250413 Hoeppner Oct 2009 A1
20090253566 Chavarria Oct 2009 A1
20090289014 Hoeppner Nov 2009 A1
20100055087 Higgins et al. Mar 2010 A1
20100140182 Chapman et al. Jun 2010 A1
20100186676 Van Der Berg Jul 2010 A1
20100206798 Dorian et al. Aug 2010 A1
20100256595 Leach et al. Oct 2010 A1
20100323870 Leach et al. Dec 2010 A1
20100324450 Leach et al. Dec 2010 A1
20110014705 Leach et al. Jan 2011 A1
20110020196 Grippi et al. Jan 2011 A1
20110021334 Leach et al. Jan 2011 A1
20110036786 Ellsworth Feb 2011 A1
20110056893 Leach et al. Mar 2011 A1
20110065183 Dorian et al. Mar 2011 A1
20110077596 Higgins et al. Mar 2011 A1
20110168193 Leach et al. Jul 2011 A1
20110192804 Landrigan et al. Aug 2011 A1
20110251041 Chavarria et al. Oct 2011 A1
20120015796 Leach et al. Jan 2012 A1
20140051061 Landrigan et al. Feb 2014 A1
20140054246 Landrigan et al. Feb 2014 A1
20140091048 Leach et al. Apr 2014 A1
20140275497 Leach et al. Sep 2014 A1
20140349388 Dorian et al. Nov 2014 A1
20140356446 Leach et al. Dec 2014 A1
Foreign Referenced Citations (84)
Number Date Country
696278 Jan 1999 AU
9103724 Mar 1993 BR
1321138 Aug 1993 CA
2182862 Jun 1996 CA
2448415 Dec 2002 CA
1074709 Jul 1993 CN
1321103 Nov 2001 CN
1322146 Nov 2001 CN
103702729 Apr 2014 CN
56103 Oct 1860 DE
1443359 Nov 1968 DE
4202667 May 1993 DE
090997 Oct 1983 EP
0102773 Mar 1984 EP
0109374 May 1984 EP
0142339 May 1985 EP
0244834 Nov 1987 EP
0253198 Jan 1988 EP
0295771 Dec 1988 EP
0417818 Mar 1991 EP
0534178 Mar 1993 EP
534178 Mar 1993 EP
0592242 Apr 1994 EP
1005910 Jun 2000 EP
1006360 Jun 2000 EP
1289618 Mar 2003 EP
1406492 Apr 2004 EP
1427279 Jun 2004 EP
1467746 Oct 2004 EP
1509326 Mar 2005 EP
1670315 Jun 2006 EP
1716901 Nov 2006 EP
2558143 Feb 2013 EP
854715 Nov 1960 GB
60-053845 Mar 1985 JP
60250014 Dec 1985 JP
2036872 Feb 1990 JP
02071747 Mar 1990 JP
2000-189407 Jul 2000 JP
2000199760 Jul 2000 JP
02129224 Oct 2000 JP
2004-305439 Nov 2004 JP
2005013783 Jan 2005 JP
200598704 Apr 2005 JP
2005098704 Apr 2005 JP
2005524451 Aug 2005 JP
2006-305365 Nov 2006 JP
2006527025 Nov 2006 JP
2008104789 May 2008 JP
2009-155234 Jul 2009 JP
WO-8400905 Mar 1984 WO
WO-8802259 Apr 1988 WO
WO-9010031 Sep 1990 WO
WO-9222312 Dec 1992 WO
WO-9305067 Mar 1993 WO
WO-9308904 May 1993 WO
WO-9407548 Apr 1994 WO
WO-9617871 Jun 1996 WO
WO-9617871 Jun 1996 WO
WO-9848938 Nov 1998 WO
WO-0061256 Oct 2000 WO
WO-0074713 Dec 2000 WO
WO-0103756 Jan 2001 WO
WO-0183068 Nov 2001 WO
WO-0238610 May 2002 WO
WO-02060925 Aug 2002 WO
WO-02098566 Dec 2002 WO
WO-03015800 Feb 2003 WO
WO-03024215 Mar 2003 WO
WO-03053362 Jul 2003 WO
WO-03088905 Oct 2003 WO
WO-03092894 Nov 2003 WO
WO-03099412 Dec 2003 WO
WO-2004009207 Jan 2004 WO
WO-2004104553 Dec 2004 WO
WO-2005034843 Apr 2005 WO
WO-2006041406 Apr 2006 WO
WO-2007127834 Nov 2007 WO
WO-2007142908 Dec 2007 WO
WO-2008127639 Oct 2008 WO
WO-2009021257 Feb 2009 WO
WO-2009111338 Sep 2009 WO
WO-2011008836 Jan 2011 WO
WO2011130173 Oct 2011 WO
Non-Patent Literature Citations (174)
Entry
Japanese Office Action mailed May 20, 2014 for Japanese Application No. JP2012-503768.
Japanese Office Action mailed Sep. 9, 2014 for Japan Patent Application No. 2012-520742,which claims benefit of PCT/US2010/041942 filed Jul. 14, 2010, which claims benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009.
“Caps for Corning® and Costar® Plastic Labware,” Technical Bulletin. (Dec. 2008) Corning, Incorporated.
“Cell Isolation Techniques, Methods and Materials, Working with Enzymes,” (2004) (9 pages) Worthington Biochemical Corp.
“Cell Isolation Theory, Tissue Types,” (2004) (5 pages) Worthington Biochemical Corp.
“Centrifuge Tubes” Corning Costar brochure. 1996/1997 Catalog pp. 76-77.
“Clotalyst® Autologous Clotting Factor” brochure. (Aug. 15, 2008) Biomet Biologics.
“Clotalyst® Autologous Clotting Factor. Would you like to have an autologous thrombin for rapid clotting and haemostasis?” Brochure. Biomet Biologics (Aug. 15, 2008).
“Corning® 15 and 50 mL Centrifuge Tubes,” Life Sciences. (Jun. 2005) Corning Incorporated.
“Cytori Celution Cell Concentrate Device,” Exhibit 14, 510(k) Summary, FDA approval K060482 (Sep. 28, 2006).
“Frequently Asked Questions, 1. Kits, 2. Enzymes,” (2003) 3 pages Worthington Biochemical Corp.
“Letter CryoSeal FS System. Vaccines, Blood & Biologics,” letter. (Jul. 26, 2007) FDA U.S. Food and Drug Administation. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm091631.htm (Web accessed Aug. 12, 2011).
“MarrowStim™ Concentration Kit Peripheral Arterial Disease (PAD) Study” brochure. Web. Jul. 2, 2009 http://www.biomet.com/patients/clinical—recruitment—padstudy.cfm.
“MarrowStim™ Concentration System,” brochure. Biomet Biologics Jun. 15, 2008.
“Plasmax® Plasma Concentration System” brochure. (Jun. 15, 2008) Biomet® Biologics.
“Prosys PRP Kit,” brochure Tozai Holdings, Inc. http://tozaiholdings.en.ec21.com/Prosys—PRP—Kit--5467051—5467061.html Printed from Web Aug. 24, 2011.
“Prosys PRP Kit,” Tozai Holdings, Inc. EC21 Global B2B Marketplace http://www.ec21.com/product-details/Prosys-PRP-Kit--5467061.html Printed from Web Jul. 18, 2011.
“ThermoGenesis Corp. to Supply Autologous Thrombin Kits to Biomet, Inc.,” PR Newslink: http:/tinyurl.com/4h3up. (Apr. 5, 2005) http://www.noblood.org/press-releases/2128-thermogenesis-corp-supply-autologous-thrombin-kits-biomet-inc [web accessed Sep. 27, 2011].
“Trypsinization of Adherent Cells,” (undated) 2 pages.
“Trypsinizing cells.” Bart's Cookbook, Web. Apr. 14, 2010. http://pingu.salk.edu/˜sefton/Hyper—protocols/trypsin.html.
Anesthesiology, vol. 81, No. 4, pp. 1074-1077, Oct. 1994, Hiromasa Mitsuhata, M.D., et al., “An Anaphylactic Reaction to Topical Fibrin Glue”.
Ann Thorac Surg, vol. 53, pp. 530-531, 1992, Mehmet C. Oz, M.D., et al., “Autologous Fibrin Glue From Intraoperatively Collected Platelet-Rich Plasma”.
Ann Thorac Surg, vol. 56, pp. 387-389, 1993, Robert L. Quigley, M.D., et al., “Intraoperative Procurement of Autologous Fibrin Glue”.
Badiavas, et al., “Treatment of Chronic Wounds With Bone Marrow-Derived Cells,” (Reprinted) Arch Dermatol. 139:510-516 (Apr. 2003).
Bang, N.U., et al., “Plasma Protein Requirements for Human Platelet Aggregation” Ann. N.Y. Acad Sci, 201:280-299 (1972).
Berguer, R., R. L. Staerkel, E. E. Moore, F. A. Moore, W. B. Galloway, and M. B. Mockus. “Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports.” J Trauma 31:3 (1991): 408-11.
Berruyer, M., J. Amiral, P. Ffrench, J. Belleville, O. Bastien, J. Clerc, A. Kassir, S. Estanove, and M. Dechavanne. “Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors,” J Thorac Cardiovasc Surg 105: 5 (1993): 892-7.
BioCUE™ Platelet Concentration System, Jun. 2010. (2 pages).
Biopolymers, vol. 27, pp. 763-774, 1988, Gerald Marx, “Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibral Association”.
Boomgaard, et al., “Pooled Platelet Concentrates Prepared by the Platelet-Rich-Plasma Method and Filtered with Three Different Filters and Stored for 8 Days.” Vox Sanq, vol. 68: 82-89, Feb. 1995.
Brodke, et al., “Bone Grafts Prepared with Selective Cell Retention Technology Heal Canine Segmental Defects as Effectively as Autograft”, SCR-Enriched Bone Grafts Heal Canine Segmental Defects, Journal of Orthopaedic Research (May 2006) pp. 857-866.
Casali, B., F. Rodeghiero, A. Tosetto, B. Palmieri, R. Immovilli, C. Ghedini, and P. Rivasi. “Fibrin glue from single-donation autologous plasmapheresis.” Transfusion 32:7 (1992): 641-3.
Clayden J D Et Al: “Improved segmentation reproducibility in group tractography using a quantitative tract similarity measure” Neuroimage, Academic Press, Orlando, FL, US LNKD-DOI: 10.1016/J.Neuroimage. 2006.07.016, vol. 33, No. 2, Nov. 1, 2006, pp. 482-492.
Clotalyst™ Automatic Clotting Factor, Would you like to have an autologous thrombin for rapid clotting and haemostasis?, brochure, Biomet Biologics, Inc., Feb. 2007 (12 pages).
Collier, B.S. et al., “The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH”, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md. 20014, Blood, vol. 47, No. 5 (May 1976).
Connolly, “Injectable Bone Marrow Preparations to Stimulate Osteogenic Repair,” Clinical Orthopaedics and Related Research 313:8-18 (Apr. 1995).
Connolly, John, M.D., et al. “Development of an Osteogenic Bone-Marrow Preparation.” The Journal of Bone and Joint Surgery, Incorporated. vol. 71-A, No. 5 (Jun. 1989) pp. 684-691.
Dallari, et al., “In Vivo Study on the Healing of Bone Defects Treated with Bone Marrow Stromal Cells, Platelet-Rich Plasma, and Freeze-Dried Bone Allografts, Alone and in Combination,” Healing of Bone Defects, Journal of Orthopaedic Research (May 2006) pp. 877-888.
De Ugarte, et al., “Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow,” Cells Tissues Organs 174:101-109 (2003).
De Ugarte, et al., “Differential Expression of Stem Cell Mobilization-Associated Molecules on Multi-Lineage Cells from Adipose Tissue and Bone Marrow,” Immunology Letters 89:267-270 (2003).
De Wit, et al. “Experiments on the Preparation of Blood Components with the IBM 2991 Blood Cell Processor” Vox Sang. 29: 352-362 (Feb. 10, 1975).
DelRossi, A. J., A. C. Cernaianu, R. A.Vertrees, C. J. Wacker, S. J. Fuller, J. Cilley Jr., and W. A. Baldino. “Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass.” J Thorac Cardiovasc Surg 100:2 (Aug. 1990): 281-6.
DePalma, L., et al., “The preparation of fibrinogen concentrate for use as fibrin glue by four different methods.” Transfusion (1993) vol. 33, No. 9; pp. 717-720.
DeUgarte, M.D., Daniel A., et al., “Future of Fat as Raw Material for Tissue Regeneration,” (Feb. 2003) pp. 215-219, Lippincott Williams & Wilkins, Inc.
DiMuzio, Paul et al., “Development of a Tissue-Engineered Bypass Graft Seeded with Stem Cells,” Vasucular, vol. 14, No. 6, (2006) pp. 338-342, BC Decker, Inc.
Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946-952, Dec. 1988, Dennis F. Thompson, et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat”.
Edlich, Richard F., George T. Rodeheaver, and John G. Thacker. “Surgical Devices in Wound Healing Management.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 581-600. 1st ed., vol. Philadelphia: W.B. Saunders Company, 1992.
Ehricke H H Et Al: “Visualizing MR diffusion tensor fields by dynamic fiber tracking and uncertainty mapping” Computers and Graphics, Elsevvier, GB LNKD-DOI: 10.1016/J.CAG.2006.01.031, vol. 30, No. 2, Apr. 1, 2006, pp. 255-264.
Eppley, et al., “Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing,” Plastic and Reconstructive Surgery, 114(6):1502-1508 (Nov. 2004).
Epstein, G. H., R. A. Weisman, S. Zwillenberg, and A. D. Schreiber. “A new autologous fibrinogen-based adhesive for otologic surgery.” Ann Otol Rhinol Laryngol 95 (May 25-26, 1985) 40-5.
European Communication Pursuant to Article 94(3) EPC mailed May 6, 2013 for PCT/US2010/029957 which claims benefit of U.S Appl. No. 12/417,789, filed Apr. 3, 2009.
Fibrostik™ Plasma Concentrator, Attention Operating Surgeon, Cell Factor Technologies, Inc., Jul. 2003.
First clinical results: Kuderma, H. and Helene Matras. “Die klinische Anwendung der Klebung van Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven.” Wein Klin Wochenschr 87 (Aug. 15, 1975): 495-501.
Floryan, K. et al. “Home Study Program: Intraoperative Use of Autologous Platelet-Rich and Platelet-Poor Plasma for Orthopedic Surgery Patients” vol. 80, No. 4 (Oct. 2004) p. 667-674.
Frasier, John K., et al., “Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes,” Nature Clinical Practice Cardiovascular Medicine, vol. 3, Supplement 1 (Mar. 2006) pp. S33-S37.
Friesen, M.D., Robert, et al. “Blood Conservation During Pediatric Cardiac Surgery: Ultrafiltration of the Extracorporeal Circuit Volume After Cardiopulmonary Bypass.” Anesth. Analg 1993: 77-702-7.
Galois, et al., “Cartilage Tissue Engineering: State-of-the-Art and Future Approaches,” Pathol Biol (Paris), 53(10), Dec. 2005.
Gibble, J. W. and P. M. Ness. “Fibrin glue: the perfect operative sealant?” Transfusion 30 (1990): 741-7.
Gimble, Jeffrey M., “Adipose-Derived Stem Cells for Regenerative Medicine,” Circulation Research (May 11, 2007) pp. 1249-1260, American Heart Association, Inc.
Gomillion, Cheryl T., et al., “Stem cells and adipose tissue engineering,” Biomaterials 27, Science Direct (2006) pp. 6052-6063, Elsevier.
GPS® III System, GPS® III Platelet Separation System, Leadership through Technology, brochure, Jul. 2007 (8 sheets).
GPS® System, “GPS® Platelet Concentrate System,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (Feb. 29, 2004) (9 pages).
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” brochure, Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 6 pages.
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 3 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
GPS® II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Biomet Biologics (Jul. 15, 2006) 16 pages.
GPS® II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Cell Factor Technologies, Inc., Biomet Europe (2005) 16 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
GPS® II System, Gravitational Platelet Separation System, “User Manual,” Cell Factor Technologies, Inc., Biomet Europe [date unknown] 13 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Grove, et al., “Plasticity of Bone Marrow-Derived Stem Cells,” Stem Cells: Concise Review, Jan. 22, 2004.
Guilak, Frank, et al., “Adipose-derived adult stem cells for cartilage tissue engineering,” Biorheology 41 (2004) pp. 389-399, IOS Press.
Harris, E.L.V. Concentration of the Extract. In. Protein Purification Methods: A Practical Approach Harris, E.L.V.; Angal, S.; Editors. (1989) Publisher: (IRL Press, Oxford, UK), pp. 67-69.
Hartman, A. R., D. K. Galanakis, M. P. Honig, F. C. Seifert, and C. E. Anagnostopoulos. “Autologous whole plasma fibrin gel. Intraoperative procurement.” Arch Surg 127 (Mar. 1992): 357-9.
Harvest SmartPrep PRP-20 Procedure Pack, “Instructions for Use” (date unknown).
Harvest Technologies brochure, SmartPrep2 (2002).
Hattori, et al., “Osteogenic Potential of Human Adipose Tissue-Derived Stromal Cells as an Alternative Stem Cell Source,” Cells Tissues Organs (2004) 178:2-12 Karger.
Haynesworth, S.E. et al. “Mitogenic Stimulation of Human Mesenchymal Stem Cells by Platelet Releasate Suggests a Mechanism for Enhancement of Bone Repair by Platelet Concentrate” 48th Annual Meeting of the Orthopaedic Research Society Poster No. 0462 (2002).
Hennis, H. L., W. C. Stewart, and E. K. Jeter. “Infectious disease risks of fibrin glue [letter].” Ophthalmic Surg 23 (Sep. 1992): 640.
Hernigou, et al., “Percutaneous Autologous Bone-Marrow Grafting for Nonunions. Influence of the Number and Concentration of Progenitor Cells,” Journal of Bone & Joint Surgery, 87-A(7):1430-1437 (Jul. 2005).
Hom, D., et al. “Promoting Healing with Recombinant Human Platelet-Derived Growth Factor-BB in a Previously Irradiated Problem Wound.” The Laryngoscope, vol. 113 (pp. 1566-1671) Sep. 2003.
Hood, Andrew G., et al., “Perioperative Autologous Sequestration III: A New Physiologic Glue with Wound Healing Properties,” (Jan. 1993) vol. 14 pp. 126-129.
International Preliminary Examination Report and Written Opinion issued Aug. 31, 2010 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008, which priority is also claimed of said provisional case by U.S. Appl. No. 12/395,085, filed Feb. 27, 2009.
International Preliminary Report on Patentability and Written Opinion mailed Oct. 13, 2011 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
International Preliminary Report on Patentability and Written Opinion mailed Oct. 31, 2013 for PCT/US2012/034104 claiming benefit of U.S. Appl. No. 13/089,591, filed Apr. 19, 2011.
International Preliminary Report on Patentability completed Aug. 13, 2009 for PCT/US2008/004687 claiming benefit of U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
International Preliminary Report on Patentability mailed Jan. 26, 2012 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009.
International Search Report and Written Opinion mailed Aug. 9, 2011 for PCT/US2011/031954 claiming benefit of U.S. Appl. No. 12/758,127, filed Apr. 12, 2010.
International Search Report and Written Opinion mailed Jul. 2, 2008 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
International Search Report and Written Opinion mailed Jul. 3, 2009 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008.
International Search Report and Written Opinion mailed Jul. 30, 2010 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
International Search Report and Written Opinion mailed Nov. 7, 2011 for PCT/US2011/045290 claiming benefit of U.S. Appl. No. 12/846,944, filed Jul. 30, 2010.
International Search Report and Written Opinion mailed Oct. 8, 2010 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009.
International Search Report for International Application No. PCT/US/0316506 mailed Oct. 13, 2003 which claims benefit of U.S. Appl. No. 60/383,013, filed May 24, 2002.
International Search Report for International Application No. PCT/US2007/012587 mailed Nov. 6, 2007 which claims benefit of U.S. Appl. No. 11/441,276, filed May 25, 2006.
International Search Report for PCT/US2012/034104 mailed Oct. 29, 2012, claiming benefit of U.S. Appl. No. 13/089,591, filed Apr. 18, 2012.
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee mailed Aug. 6, 2012 for PCT/US2012/034104 claiming benefit of U.S. Appl. No. 13/089,591, filed Apr. 19, 2011.
Ishida, et al., “Platelet-Rich Plasma With Biodegradable Gelatin Hydrogel Promotes Rabbit Meniscal Tissue Regeneration,” 52nd Annual Meeting of the Orthopaedic Research Society Paper No. 1035, 1 page (2006).
Jackson, C. M. and Y. Nemerson. “Blood coagulation.” Annu Rev Biochem 49 (1980): 765-811).
Japan Office Action mailed Jan. 22, 2013 for Japan Application No. 2010-503066.
Jayadev, Suprya. “Trypsinization of Adherent Cells.” Aug. 8, 1991. Web. Apr. 14, 2010 http://www.duke.edu/web/ceramide/protocols/0005.html.
Johnstone, et al., “Autologous Mesenchymal Progenitor Cells in Articular Cartilage Repair”, Clinical Orthopaedics and Related Research 367S:S156-S162 (Oct. 1999).
Jones D K et al: “Confidence mapping in diffusion ensor magnetic resonance imaging tractography using a bootstrap approach” Magnetic Resonance in Medicine Wiley USA, vol. 53 , No. 5, May 2005, pp. 1143-1149.
Jorgensen, et al., “Stem Cells for Repair of Cartilage and Bone: The Next Challenge in Osteoarthritis and Rheumatoid Arthritis,” Annals of Rheumatic Diseases, Aug. 2000.
Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605-611, Helene Matras, M.D., “Fibrin Seal: The State of the Art” (1985).
Karpatkin, S., “Heterogeneity of Human Platelets. VI., Correlation of Platelet Function with Platelet Volume”, Blood, vol. 51, No. 2 (Feb. 1978).
Kjaergard, H. K,, U. S. Weis-Fogh, H. Sorensen, J. Thiis, and I. Rygg. “A simple method of preparation of autologous fibrin glue by means of ethanol.” Surg Gynecol Obstet 175 (1992): 72-3.
Kjaergard, H. K., Fogh Us Weis, and J. J. Thiis. “Preparation of autologous fibrin glue from pericardial blood.” Ann Thorac Sur 55 (1993): 543-4.
Kumar, Vijay et al. “Stability of Human Thrombin Produced From 11 ml of Plasma Using the Thrombin Processing Device,” Journal of American Society of Extra-Corporeal Technology. JECT: Mar. 2005:37; 390-395.
Kumar, Vijay et al. “Whole Blood Thrombin: Development of a Process for Intra-Operative Production of Human Thrombin.” Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2007; 39:18-23.
Kumar, Vijay et al., “Autologous Thrombin: Intraoperative Production From Whole Blood.” Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2008; 40:94-98.
Laryngoscope vol. 99, pp. 974-976, Sep. 1989, Kyosti Laitakari, M.D., et al., “Autologous and Homologous Fibrinogen Sealants: Adhesive Strength”.
Laryngoscope, vol. 95, pp. 1074-1076, Sep. 1985, Karl H. Siedentop, M.D., et al., “Autologous Fibrin Tissue Adhesive”.
Laryngoscope, vol. 96, pp. 1062-1064, Oct. 1986, Karl H. Siedentop, M.D., et al., “Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made from Patient's Own Blood”.
Lasher, Lisa, M.D., “My Experience with PRP,” PowerPoint presentation, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Lendeckel, Stefan, et al., “Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report,” Journal of Cranio-Maxillofacial Surgery (2004) European Association for Cranio-Maxillofacial Surgery.
Lerner, R. and N. S. Binur. “Current status of surgical adhesives.” J Surg Res 48 (Feb. 1990): 165-81.
Longas, Maria O., “An Improved Method for the Purification of Human Fibrinogen.” J. Biochem (1980) vol. 11, pp. 559-564.
Lori N F Et Al: “Diffusion tensor fiber tracking of human brain connectivity: acquisition methods, reliability analysis and biological results” NMR in Biomedicine Wiley UK, vol. 15, No. 7-8, Nov. 2002, pp. 493-515.
Lu, et al., “Bone Marrow Mesenchymal Stem Cells: Progress in Bone/Cartilage Defect Repair,” 19(1), Jan. 2002.
Marrowstim Concentration System, Biomet Biologics, Inc., 20 pages (REV Feb. 15, 2008).
Marx, Gerard, et al., “Heat Denaturation of Fibrinogen to Develop a Biomedical Matrix.” Journal of Biomedical Materials Research Part B: Applied Biomaterials (Apr. 2007) pp. 49-57.
Masri, Marwan A., et al. “Isolation of Human Fibrinogen of High Purity and in High Yield Using Polyethylene Glycol 1000.” Thromb Haemostas (Struttgart) (1983) vol. 49 (2); pp. 116-119.
Matras, Helene, H. P. Dinges, H. Lassmann, and B. Mamoli. “Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment.” Wein Med Woschtr 122:37 (1972): 517-523.
Minntech® Filtration Technologies Group, “Hemocor HPH® Hemoconcentrator,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/hph/index.html, printed Jul. 15, 2004 (2 pages).
Minntech® Filtration Technologies Group, “Medical Applications: Blood Filtration” Minntech Corporation (2004); http://www.minntech.com/ftg/industries/medical/blood—filter.html, printed Jul. 15, 2004 (1 page).
Minntech® Filtration Technologies Group, “Renaflo® II Hemofilter,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/renaflo/index.html, printed Jul. 15, 2004 (2 pages).
Molnar, Amy, “Stem Cells from Muscles Can Repair Cartilage, Study Finds Genetically Engineered Muscle-Derived Stem Cells Improved Cartilage Repair in Rats”, American College of Rheumatology, (2005).
Moretz, W., Jr., J Shea Jr., J. R. Emmett, and J Shea. “A simple autologous fibrinogen glue for otologic surgery.” Otolaryngol Head Neck Surg 95 (Jul. 1986): 122-4.
Nakagami, Hironori, et al., “Novel Autologous Cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells,” Angiogenesis by Adipose Tissue-Derived Cells, (Dec. 2005) pp. 2542-2547, American Heart Association, Inc.
Nathan, Suresh,, et al., “Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue,” Tissue Engineering, vol. 9, No. 4 (2003) pp. 733-744 Mary Ann Liebert, Inc.
Nilsson, et al., “Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs,” The Journal of Bone and Joint Surgery, vol. 68 B., No. 4, Aug. 1986.
Notice of Allowance mailed May 27, 2010 for U.S. Appl. No. 12/101,594, filed Apr. 11, 2008.
Orphardt, Charles E., “Denaturation of Proteins,” Virtual Chembook, Elmhurst College (2003) 3 pages. http://www.elmhurstedu/˜chm/vchembook/568denaturation.html (web accessed Mar. 9, 2011).
Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203-209, Feb. 1994, Dean M. Toriumi, M.D., et al., “Surgical Tissue Adhesives in Otolaryngology-Head and Neck Surgery”.
Parchment et al., Roles for in vitro myelotoxicity tests in preclincial drug development and clinical trial planning, Toxicology Pathology, Society of Toxicological Pathologists, vol. 21, No. 2, 1993, pp. 241-250.
Parchment et al., Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning, Toxicology Pathology, Society of Toxicological Pathologists, vol. 21, No. 2, 1993, pp. 241-250.
Parker, Anna M., et al., Adipose-derived stem cells for the regeneration of damaged tissues, Expert Opinion, Cell- & Tissue-based Therapy, Expert Opin. Biol. Ther. (2006) pp. 567-578 Informa UK Ltd.
Planat-Bénard, V., et al., “Spontaneous Cardiomyocyte Differentiation From Adipose Tissue Stroma Cells,” Adipose-Derived Cell Cardiomyocyte (Feb. 6, 2004) pp. 223-229 American Heart Association, Inc.
Ponticiello, Michael S., “A Rapid Technique for the Isolation and Concentration of Stem Cells from Human Bone Marrow”, Cell Factor Technologies, Inc. (2006) 2 pages.
Rangappa, Sunil, M.D., “Transformation of Adult Mesenchymal Stem Cells Isolated From the Fatty Tissue Into Cardiomyocytes,” Adult Stem Cells Transformed into Cardiomyoctyes, (2003) pp. 775-779 Ann Thorac Surg.
Rigotti, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007) pp. 1409-1422.
Rubin, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Discussion vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007) pp. 1423-1424.
Sanal, M. “Does fibrin glue cause foreign body reactions? [letter].” Eur J Pediatr Surg 3 (1992): 190 (1 page).
Sanal, M., H. Dogruyol, A. Gurpinar, and O. Yerci. “Does fibrin glue cause foreign body reactions?” Eu r J Pediatr Surg 2 (1992): 285-6.
Schmidt, K.G., et al., “Labelling of Human and Rabbit Platelets with Indium-Oxine Complex”, 23:97-106 (1979).
Schmidt, K.G., et al., “Preparation of Platelet Suspensions from Whole Blood in Buffer”, Scand. J. Hoemato, 23:88-96 (1979).
Schäffler, Andreas, et al., “Concise Review: Adipose Tissue-Derived Stromal Cells—Basic and Clinical Implications for Novel Cell-Based Therapies,” Tissue-Specific Stem Cells, Stem Cells® (Apr. 10, 2007) pp. 818-827 AlphaMed Press.
Semple, Elizabeth, PhD, et al. “Quality of Thrombin Produced From the Patient's Own Plasma Using the TPD™, a New Thrombin-Processing Device.” Journal of American Society of Extra-Corporeal Technology. JECT: 2005; 37:196-200.
Sierra, D. H. “Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications.” J Biomater Appl 7 (Apr. 1993): 309-52.
Sigma-Aldrich® Alkaline Phosphatase (Procedure No. 85), drug fact sheet, (2003) pp. 1-2, Sigma-Aldrich, Inc.
Silver, Frederick H., et al., “Review Preparation and use of fibrin glue in surgery.” Biomaterials 16 (1995) pp. 891-903.
Solem, Jan Otto, et al., “Hemoconcentration by Ultrafiltration During Open-Heart Surgery,” Scand J Thor Cardiovasc Surg 22:271-274, 1988.
Sutton, Robin G., et al. “Comparison of Three Blood-Processing Techniques During and After Cardiopulmonary Bypass.” Ann Thorac Surg (1993) vol. 56; pp. 941-943.
Swift, Mathew J., et al., “Characterization of Growth Factors in Platelet Rich Plasma,” 1-Cell Factor Technologies, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005.
Symphony II Platelet Concentrate System/PCS brochure; “Increasing bone graft bioactivity through reproducible concentrations of natural growth factors,” DePuy (Jan. 2003).
Takahashi, Kazutoshi et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, (Nov. 30, 2007) pp. 1-12, Elsevier Inc.
The American Journal of Surgery, vol. 168, pp. 120-122, Aug. 1994, Roy L. Tawes, Jr., M.D., et al., “Autologous Fibrin Glue: The Last Step in Operative Hemostatis”.
The American Surgeon, vol. 55, pp. 166-168, Mar. 1989, William D. Spotnitz, M.D., et al., “Successful Use of Fibrin Glue During 2 Years of Surgery at a University Medical Center”.
The Sports Medicine Center, “Knee Cartilage Implantation”, Carticel™, “Autologous Cultured Chondrocyte Implantation”, http://www.orthoassociates.com/carticel.htm (printed Apr. 6, 2006).
The Stone Clinic, “Platelet Rich Plasma (PRP)”, web site printed May 2006.
Weis-Fogh, U. S. “Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system.” Eur Surg Res 20 (1988): 381-9.
Weisman, MD., Robert A., “Biochemical Characterization of Autologous Fibrinogen Adhesive,” Laryngoscope 97: Oct. 1987; pp. 1186-1190.
Wiseman, David M., David T. Rovee, and Oscar M. Alverez. “Wound Dressings: Design and Use.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 562-580. 1st ed., vol. Philadelphia: W. B. Saunders Company, 1992.
Woodell-May, et al., “Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting,” Scientific Foundation, Journal of Carniofacial Surgery 16(5):749-756 (Sep. 2005).
Written Opinion of the International Preliminary Examining Authority mailed Mar. 17, 2009 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007.
Yoon, Eulsik, M.D., Ph.D., et al., “In Vivo Osteogenic Potential of Human Adipose-Derived Stem Cells/Poly Lactide-Co-Glycolic Acid Constructs for Bone Regneration in a Rat Critical-Sized Calvarial Defect Model,” Tissue Engineering, vol. 13, No. 3 (2007) pp. 619-627 Mary Ann Liebert, Inc.
Zhang, Duan-zhen, et al., “Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction,” Chinese Medical Journal, vol. 120, No. 4 (2007) pp. 300-307 General Hospital of Shenyang Military Region, Shenyang, China.
Zuk, Patricia A., Ph.D., “Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies,” Tissue Engineering, vol. 7, No. 2, (2001) pp. 211-228 Mary Ann Liebert, Inc.
International Preliminary Report on Patentability and Written Opinion mailed on Mar. 12, 2015 for PCT/US2013/056793 claiming benefit of U.S. Appl. No. 13/595,461, filed Aug. 27, 2012.
International Search Report and Written Opinion mailed Dec. 5, 2013 for PCT/US2013/056793 claiming benefit of U.S. Appl. No. 13/595,461, filed Aug. 27, 2012.
Preliminary Notice of Reasons for Rejection for Japanese Patent Application No. 2014-024420 mailed on Feb. 24, 2015.
Chinese Office Action mailed Nov. 21, 2014 for Chinese Patent Application No. 201280030026.X.
Chinese Office Action mailed Jun. 30, 2014 for Chinese Patent Application No. 201080019707.7, which claims benefit of PCT/US2010/029957 filed Apr. 5, 2010, which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009.
Minivalve international: duckbill valves—du 054.001 sd, <http://www.minivalve.com/htm/DV054.htm>, Accessed Jun. 30, 2014, 1 page.
Momentive Silopren*LSR 2050, Jun. 30, 2014, 3 pages
Vernay Product Information Sheet, Umbrella Check Valve, Part No. V251010200, Jul. 2013, 2 pages.
Related Publications (1)
Number Date Country
20140088492 A1 Mar 2014 US
Divisions (1)
Number Date Country
Parent 12758127 Apr 2010 US
Child 14086482 US